Status:
UNKNOWN
Clinical Study of CMR to Evaluate the Effect of Ivabradine on the Improvement of Left Ventricular Remodeling in STEMI Patients After Primary PCI
Lead Sponsor:
Qian geng
Conditions:
Cardiovascular Diseases
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
This study aim to investigate the effect of ivabradine on reducing infarct size and improving left ventricular remodeling after in patients undergoing primary PCI for ST-elevation myocardial infarctio...
Detailed Description
Investigators will enroll 240 patients with STEMI who were admitted to the Chinese PLA General Hospital between October 2020 and October 2021，the investigators randomly assign eligible patients in a 1...
Eligibility Criteria
Inclusion
- STEMI patients: typical chest pain lasting 30 min within the previous 12 h, a clear ST-segment elevation of N0.1 mV in ≥2 contiguous electrocardiographic leads, and elevated blood levels of troponin T
- patients were scheduled to undergo diagnostic cardiac angiography or percutaneous coronary interventions
Exclusion
- had once treated by ivabradine
- history of myocardial infarction
- mechanical complications
- Unable to perform myocardial MRI
- liver and kidney failure
- malignant tumor
- unconscious
Key Trial Info
Start Date :
August 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2022
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT05348057
Start Date
August 1 2021
End Date
September 1 2022
Last Update
April 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese People's Liberation Army General Hospital
Beijing, Beijing Municipality, China, 100853